Welcome
Viral Genetics, Inc. is a biotechnology research and development company researching new treatments and methods of detection for HIV/AIDS, Lyme Disease, staph and strep, cancer and certain other autoimmune and infectious diseases. Two approaches based on patent rights licensed from the University of Colorado and University of Vermont form the basis of our research: “Targeted Peptides” and “Metabolic Disruption”. As we near completion of our preclinical research, we are preparing pre-IND applications for FDA clinical trials of compounds from these approaches in the US. We also have a subsidiary called VG Energy that is separately developing the non-disease applications of our metabolic technology.Click here for more information.
Recent News
VG Energy Highlighted in Branson's "Carbon War Room" Jet Fuel InitiativeNew website aimed at reducing the use of traditional jet fuels by as much as fifty percent
SAN MARINO, Calif.--(BUSINESS WIRE)-- Viral Genetics' (Pink Sheets: VRAL) majority owned subsidiary, VG Energy, has been highlighted in Sir Richard Branson’s Carbon War Room effort as one of the approved technologies in the accelerating evolution toward renewable sources for the bio-fuels sector. VG Energy's algae “lipid trigger” technology tricks algae into storing energy as fat, rather than carbohydrates. In ongoing studies, VG Energy's...
Click here for more information.
Metacytolytics
MetaCytoLytics is a subsidiary of Viral Genetics that is focused on the development of our Metabolic Disruption technology that has application in the treatment of various diseases including cancer through the manipulation of how certain types of cells use or store fats and sugars to generate internal energy.Through manipulation of tumor cells’ metabolisms, we are studying how to cause their death and are working to develop treatments for drug resistant tumors — the leading cause of death from cancer. Currently the company is working at development of a compound for the treatment of glioblastoma, a deadly form of brain cancer, and has planned an investigator’s IND for January 2011.
Click here for more information.